Compare · HYPD vs NVO
HYPD vs NVO
Side-by-side comparison of Hyperion DeFi Inc. (HYPD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 3570.1x HYPD ($48.6M).
- Over the past year, HYPD is down 60.5% and NVO is down 28.6% - NVO leads by 31.9 points.
- HYPD has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for HYPD).
- Company
- Hyperion DeFi Inc.
- Novo Nordisk A/S
- Price
- $2.87-8.60%
- $38.82-1.05%
- Market cap
- $48.6M
- $173.66B
- 1M return
- -17.29%
- -10.14%
- 1Y return
- -60.52%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 4
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HYPD
- Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.
- Hyperion DeFi Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
- Chief Financial Officer Knox David R. covered exercise/tax liability with 19,563 shares, decreasing direct ownership by 6% to 287,556 units (SEC Form 4) (withholding tax)
- Hyperion DeFi, Anchorage Digital, and HyperLend Together Announce the First Institutional Credit Facility on Hyperliquid
- Hyperion DeFi Supports D3’s Frontier Vault Launch, Bringing Internet Domain Priority Access to the Hyperliquid Ecosystem
- Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds
- Hyperion DeFi Raises Guidance and Announces $20M Share Repurchase Program
- Officer Jung Hyunsu covered exercise/tax liability with 40,000 shares, decreasing direct ownership by 3% to 1,345,676 units (SEC Form 4) to satisfy withholding tax
- SEC Form 10-Q filed by Hyperion DeFi Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank